Intellia Updates Investors on Nex-Z Trial Safety Hold

Intellia Therapeutics ( (NTLA) ) just unveiled an update.

On January 9, 2026, Intellia Therapeutics updated its corporate presentation to investors, detailing the status of its CRISPR-based pipeline and providing additional disclosure on a serious safety event tied to its lead ATTR amyloidosis candidate, nexiguran ziclumeran (nex-z). The company reiterated that a patient in the Phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy experienced Grade 4 liver transaminase elevations and increased bilirubin, triggering a protocol-mandated trial pause and prompting the U.S. Food and Drug Administration to impose a clinical hold on both the MAGNITUDE and MAGNITUDE-2 Phase 3 studies; the patient subsequently died on November 5, 2025, with the principal investigator attributing the death to septic shock from a perforated duodenal ulcer amid a complex clinical course that included acute liver injury treated with corticosteroids. Intellia reported that more than 650 patients with ATTR-CM and 47 patients with hereditary ATTR amyloidosis with polyneuropathy have been enrolled across the two trials, with Grade 4 liver enzyme elevations observed in less than 1% of MAGNITUDE participants and none in MAGNITUDE-2, and said it will update stakeholders once it has agreed with regulators on a path forward for nex-z, underscoring both the regulatory risk around its flagship ATTR program and the broader safety and development uncertainties facing first-in-class in vivo CRISPR therapies.

The most recent analyst rating on (NTLA) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Spark’s Take on NTLA Stock

According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.

Intellia Therapeutics’ overall stock score reflects the significant challenges it faces in its financial performance and valuation, typical of a biotech firm in its growth phase. The technical analysis provides a neutral outlook, while the earnings call highlights both progress and significant setbacks, particularly the clinical hold on key trials. The company’s strong cash position offers some stability, but the risks associated with its clinical trials and financial losses weigh heavily on its score.

To see Spark’s full report on NTLA stock, click here.

More about Intellia Therapeutics

Intellia Therapeutics is a biotechnology company developing in vivo and ex vivo CRISPR-based gene-editing therapies, with a late-stage pipeline focused on transthyretin (ATTR) amyloidosis and hereditary angioedema (HAE). Its lead product candidates include nexiguran ziclumeran (nex-z, also known as NTLA-2001) for ATTR amyloidosis and lonvoguran ziclumeran (lonvo-z, NTLA-2002) for HAE, targeting large, high-value rare disease markets where single-dose, potentially disease-modifying treatments could reshape standards of care.

Average Trading Volume: 6,732,747

Technical Sentiment Signal: Sell

Current Market Cap: $1.17B

See more insights into NTLA stock on TipRanks’ Stock Analysis page.